These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9463852)

  • 21. An evaluation of inferential procedures for adaptive clinical trial designs with pre-specified rules for modifying the sample size.
    Levin GP; Emerson SC; Emerson SS
    Biometrics; 2014 Sep; 70(3):556-67. PubMed ID: 24766094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing.
    Tan M; Xiong X; Kutner MH
    Biometrics; 1998 Jun; 54(2):682-95. PubMed ID: 9629648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sample size determination in group-sequential clinical trials with two co-primary endpoints.
    Asakura K; Hamasaki T; Sugimoto T; Hayashi K; Evans SR; Sozu T
    Stat Med; 2014 Jul; 33(17):2897-913. PubMed ID: 24676799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive clinical trial designs with pre-specified rules for modifying the sample size: understanding efficient types of adaptation.
    Levin GP; Emerson SC; Emerson SS
    Stat Med; 2013 Apr; 32(8):1259-75; discussion 1280-2. PubMed ID: 23081665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sample size determination and re-estimation for matched pair designs with multiple binary endpoints.
    Xu J; Yu M
    Biom J; 2013 May; 55(3):430-43. PubMed ID: 23553605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the benefits of adaptive sequential designs in time-to-event endpoint settings.
    Emerson SC; Rudser KD; Emerson SS
    Stat Med; 2011 May; 30(11):1199-217. PubMed ID: 21538450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On efficient two-stage adaptive designs for clinical trials with sample size adjustment.
    Liu Q; Li G; Anderson KM; Lim P
    J Biopharm Stat; 2012; 22(4):617-40. PubMed ID: 22651105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategies for including patients recruited during interim analysis of clinical trials.
    Faldum A; Hommel G
    J Biopharm Stat; 2007; 17(6):1211-25. PubMed ID: 18027227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficient group sequential designs when there are several effect sizes under consideration.
    Jennison C; Turnbull BW
    Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Group sequential designs for three-arm 'gold standard' non-inferiority trials with fixed margin.
    Schlömer P; Brannath W
    Stat Med; 2013 Dec; 32(28):4875-89. PubMed ID: 23970488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Group sequential and discretized sample size re-estimation designs: a comparison of flexibility.
    Wu X; Cui L
    Stat Med; 2012 Oct; 31(24):2844-57. PubMed ID: 22733405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blinded sample size recalculation in clinical trials with binary composite endpoints.
    Sander A; Rauch G; Kieser M
    J Biopharm Stat; 2017; 27(4):705-715. PubMed ID: 27295402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple-stage sampling procedure for covariate-adjusted response-adaptive designs.
    Park E; Chang YC
    Stat Methods Med Res; 2016 Aug; 25(4):1490-511. PubMed ID: 23723174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials.
    Mi MY; Betensky RA
    Clin Trials; 2013 Apr; 10(2):207-15. PubMed ID: 23283576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Planning and revising the sample size for a trial.
    Gould AL
    Stat Med; 1995 May 15-30; 14(9-10):1039-51; discussion 1053-5. PubMed ID: 7569499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptive group sequential test for clinical trials with changing patient population.
    Feng H; Shao J; Chow SC
    J Biopharm Stat; 2007; 17(6):1227-38. PubMed ID: 18027228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re-evaluating design specifications of longitudinal clinical trials without unblinding when the key response is rate of change.
    Shih WJ; Gould AL
    Stat Med; 1995 Oct; 14(20):2239-48. PubMed ID: 8552900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A practical comparison of group-sequential and adaptive designs.
    Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sample size re-estimation for survival data in clinical trials with an adaptive design.
    Togo K; Iwasaki M
    Pharm Stat; 2011; 10(4):325-31. PubMed ID: 22328325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.